Description: LIDDS AB (publ), a pharmaceutical company, develops and sells pharmaceutical products for cancer and other diseases in Sweden. It is developing various drugs, such as NZ-2HOF to treat prostate cancer; NZ-DTX to treat breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX for the treatment of solid tumors; NZ-IO, an immunotherapy; NZ-STING for the treatment of immuno-oncology; and NZ-TLR9 for enhancing cancer immunotherapies. LIDDS AB (publ) has a collaboration agreement with PharmIdea SIA to focus on anti-cancer drugs and sterile formulations. The company is based in Uppsala, Sweden.
Home Page: www.liddspharma.com
Virdings allé 32b
Uppsala,
754 50
Sweden
Phone:
46 00 44 55 66
Officers
| Name | Title |
|---|---|
| Ms. Monica Wallter | Sr. Advisor |
| Mr. Anders Mansson | Chief Exec. Officer |
| Ms. Jenni Bjornulfson | CFO & Head of IR |
| Mr. Matthew Lindon | Chief Scientific Officer |
| Dr. Johan Harmenberg M.D., Ph.D. | Chief Medical Officer |
| Ms. Annette Moldrup | Chief Bus. Devel. Officer |
| Ms. Kia Bengtsson | Head of Clinical Devel. |
Exchange: ST
Country: SE : Sweden
Currency: Swedish krone (kr)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.0445 |
| Price-to-Sales TTM: | 15.3417 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 7 |